This presentation by prof. Marx is the second part of a series on tackling cardiorenal risk in patients with diabetes. He provides an overview of clinical trials with SGLT2 inhibitors and current recommendations in guidelines.
Watch the first part of a series on tackling cardiorenal risk in patients with diabetes by teaming up. Prof. Davies introduces the topic and presents a case.
The SGLT2 inhibitor empagliflozin reduced the risk of the primary endpoint, HF hospitalization and renal outcomes independently of baseline SBP, in patients with HFrEF in the EMPEROR-Reduced trial.
Reduction of CV and renal outcomes by empagliflozin in HFrEF patients in the EMPEROR-Reduced trial was independent of baseline NT-proBNP levels. Empagliflozin reduced NT-proBNP levels, which was associated with a reduction in adverse outcomes.
EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.
EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.
EASD 2021 Using data of four semaglutide trials, this exploratory analysis showed that both subcutaneous and oral semaglutide reduced high-sensitivity CRP in patients with T2DM.
EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.
EASD 2021 HbA1c, body weight and SBP were lowered by semaglutide and liraglutide, regardless of background SGLT2i therapy in diabetes patients, in a post hoc analysis of SUSTAIN 6.
EASD 2021 This analysis showed that semaglutide reduced the risk of MACE compared to placebo regardless of metformin use in patients with T2DM.
EASD 2021 In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.
EASD 2021 This analysis showed that improvements in two or more risk markers were associated with reduced risk of expanded MACE, CV death and nephropathy in patients with T2DM.